EHR

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Physician Scientist at Birthing Cultural Rigor Prioritizes Voices of Black Birthing Experience in Response to Obstetric Racism in the United States

MEMPHIS, Tenn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Black mothers die in hospitals at nearly four times the rate of White mothers...

Life sciences leaders share their experiences of scaling transformation at Indegene Digital Summit | September 22-23, 2022 | Virtual-only

Indegene Digital Summit 2022 - Keynote Speakers Keynote speakers at Indegene Digital Summit 2022 - Life Sciences' premier global thought...

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa...

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...

error: Content is protected !!